|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - NovoCure Ltd (NVCR)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-03-11 Sale |
2019-03-12 4:56 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $48.31 | $241,550 | 69,743 (Direct) |
View |
| 2019-03-04 Sale |
2019-03-06 4:18 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
90,000 | $53.94 | $4,854,312 | 315,897 (Direct) |
View |
| 2019-03-04 Sale |
2019-03-06 4:17 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $55.89 | $909,286 | 250,025 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:15 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $55.57 | $5,556,582 | 333,757 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:14 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $55.01 | $1,375,275 | 85,000 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:13 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
40,586 | $55.63 | $2,257,698 | 45,961 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:52 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
3,097 | $53.68 | $166,247 | 921,403 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:36 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
3,288 | $53.68 | $176,500 | 69,552 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:35 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
2,397 | $53.68 | $128,671 | 171,702 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:32 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
1,558 | $53.68 | $83,633 | 26,797 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:31 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $54.4 | $49,119 | 353,887 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:30 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
2,368 | $53.68 | $127,114 | 39,203 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 6:00 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
12,230 | $53.63 | $655,870 | 177,758 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:58 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,647 | $53.63 | $1,000,001 | 80,482 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:56 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
6,377 | $53.63 | $341,986 | 30,087 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:54 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
9,325 | $53.63 | $500,081 | 42,972 (Direct) |
View |
| 2019-02-12 Sale |
2019-02-14 5:10 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
50,000 | $51.46 | $2,573,000 | 203,262 (Direct) |
View |
| 2019-02-11 Sale |
2019-02-13 4:08 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $49.59 | $247,950 | 99,743 (Direct) |
View |
| 2019-02-01 Sale |
2019-02-05 4:16 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
58,500 | $49.21 | $2,878,847 | 184,058 (Direct) |
View |
| 2019-01-24 Sale |
2019-01-28 4:15 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
26,874 | $49.03 | $1,317,731 | 166,547 (Direct) |
View |
| 2019-01-25 Sale |
2019-01-28 4:13 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $50 | $1,000,000 | 104,743 (Direct) |
View |
| 2019-01-25 Sale |
2019-01-28 4:12 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $49.2 | $1,722,000 | 334,663 (Direct) |
View |
| 2019-01-23 Sale |
2019-01-25 4:12 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $47.35 | $1,657,250 | 369,663 (Direct) |
View |
| 2019-01-23 Sale |
2019-01-25 4:10 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
88,695 | $47.48 | $4,211,239 | 259,859 (Direct) |
View |
| 2019-01-18 Sale |
2019-01-22 5:14 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $45.9 | $1,376,910 | 404,663 (Direct) |
View |
| 2019-01-18 Sale |
2019-01-22 5:13 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
46,863 | $45.91 | $2,151,357 | 218,027 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:19 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $45 | $900,060 | 124,743 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:17 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
25,000 | $45 | $1,125,075 | 37,500 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:15 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
200,000 | $45.16 | $9,031,704 | 271,164 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:13 pm |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
168,813 | $45.17 | $7,624,788 | 209,063 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:12 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $45.15 | $677,250 | 181,547 (Direct) |
View |
| 2019-01-15 Sale |
2019-01-16 4:32 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $44.2 | $1,326,000 | 434,663 (Direct) |
View |
| 2019-01-14 Sale |
2019-01-16 4:31 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
200,000 | $43.51 | $8,701,200 | 346,863 (Direct) |
View |
| 2019-01-11 Sale |
2019-01-14 4:35 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
26,251 | $42 | $1,102,647 | 34,587 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:34 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $40.88 | $2,245,810 | 201,488 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:32 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $39.91 | $199,550 | 144,743 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:30 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $42.35 | $1,270,500 | 464,663 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-03-11 Exercise |
2019-03-12 4:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 69,743 (Direct) |
View |
| 2019-03-11 Exercise |
2019-03-12 4:56 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 69,743 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,766 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
40,000 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
31,234 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,766 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
40,000 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
31,234 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $14.37 | 250,025 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:17 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $14.37 | 250,025 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $14.37 | 333,757 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:15 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $14.37 | 333,757 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $3.44 | 85,000 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:14 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $3.44 | 85,000 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,439 | $11.46 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,250 | $7.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,897 | $21.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,439 | $11.46 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,250 | $7.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2028-02-26 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,897 | $21.15 | 45,961 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:52 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
9,260 | $52.9 | 921,403 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:52 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
9,260 | $0 | 921,403 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:36 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
7,717 | $52.9 | 69,552 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:36 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
7,717 | $0 | 69,552 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
6,174 | $52.9 | 171,702 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:35 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
6,174 | $0 | 171,702 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:34 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
6,945 | $52.9 | 152,408 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:34 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
6,945 | $0 | 152,408 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,087 | $52.9 | 26,797 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:32 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,087 | $0 | 26,797 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
9,260 | $52.9 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $14.37 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
9,260 | $0 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $14.37 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,556 | $52.9 | 39,203 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:30 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,556 | $0 | 39,203 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 6:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
31,200 | $53.38 | 177,758 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 6:00 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
31,200 | $0 | 177,758 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:58 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
43,333 | $53.38 | 80,482 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:58 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
43,333 | $0 | 80,482 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:57 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
36,400 | $53.38 | 145,463 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:57 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
36,400 | $0 | 145,463 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,000 | $53.38 | 30,087 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:56 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,000 | $0 | 30,087 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:54 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
21,667 | $53.38 | 42,972 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:54 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
21,667 | $0 | 42,972 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
53,333 | $53.38 | 224,497 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:51 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
53,333 | $0 | 224,497 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
32,098 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
17,902 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
32,098 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
17,902 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-11 Exercise |
2019-02-13 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 99,743 (Direct) |
View |
| 2019-02-11 Exercise |
2019-02-13 4:08 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 99,743 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
37,500 | $7.15 | 184,058 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
21,000 | $7.15 | 184,058 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 4:16 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
37,500 | $7.15 | 184,058 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 4:16 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
21,000 | $7.15 | 184,058 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-28 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 166,547 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-28 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
11,874 | $7.15 | 166,547 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-28 4:15 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 166,547 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-28 4:15 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
11,874 | $7.15 | 166,547 (Direct) |
View |
| 2019-01-25 Exercise |
2019-01-28 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 104,743 (Direct) |
View |
| 2019-01-25 Exercise |
2019-01-28 4:13 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 104,743 (Direct) |
View |
| 2019-01-25 Exercise |
2019-01-28 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $3.44 | 334,663 (Direct) |
View |
| 2019-01-25 Exercise |
2019-01-28 4:12 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $3.44 | 334,663 (Direct) |
View |
| 2019-01-23 Exercise |
2019-01-25 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $3.44 | 369,663 (Direct) |
View |
| 2019-01-23 Exercise |
2019-01-25 4:12 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,000 | $3.44 | 369,663 (Direct) |
View |
| 2019-01-23 Exercise |
2019-01-25 4:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
88,695 | $7.48 | 259,859 (Direct) |
View |
| 2019-01-23 Exercise |
2019-01-25 4:10 pm |
N/A 2024-02-25 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
88,695 | $7.48 | 259,859 (Direct) |
View |
| 2019-01-18 Exercise |
2019-01-22 5:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 404,663 (Direct) |
View |
| 2019-01-18 Exercise |
2019-01-22 5:14 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 404,663 (Direct) |
View |
| 2019-01-18 Exercise |
2019-01-22 5:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
46,863 | $3.44 | 218,027 (Direct) |
View |
| 2019-01-18 Exercise |
2019-01-22 5:13 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
46,863 | $3.44 | 218,027 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:19 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 124,743 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:19 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 124,743 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $11.85 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $19.25 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A 2027-05-02 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $11.85 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A 2027-07-25 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $19.25 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
100,000 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
68,813 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
100,000 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
68,813 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 181,547 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:12 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 181,547 (Direct) |
View |
| 2019-01-15 Exercise |
2019-01-16 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 434,663 (Direct) |
View |
| 2019-01-15 Exercise |
2019-01-16 4:32 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 434,663 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,751 | $14.37 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
17,500 | $11.46 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,751 | $14.37 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
17,500 | $11.46 | 34,587 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:34 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $14.37 | 201,488 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:34 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $14.37 | 201,488 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 144,743 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:32 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 144,743 (Direct) |
View |
| 2019-01-10 Option Award |
2019-01-14 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
25 | $27.2 | 464,663 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 464,663 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:30 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 464,663 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Mon, 25 Mar 2019 17:28:12 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |